Organized around the objective of accelerating target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions, A-Alpha Bio has developed a synthetic biology platform designed to aid in the development of drugs that interact with multiple targets. With the firm partnering with pharmaceutical companies to discover and optimize high-impact therapeutics, A=Alpha bio Inc's proprietary synthetic biology platform - designated AlphaSeq - enables screening against thousands of targets in a single experimental step. An all-at-once approach saves time, reduces cost, and improves success rates. The effort is to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
